Class: Use (236)
Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
Patent Number: 7098027This patent is useful for inducing remyelination using autologous bone marrow stem cells. Demyelination is a pathology associated with numerous neuronal degenerative diseases such as multiple sclerosis or Krabbe Disease. The patent has 1 independent claim which covers the methodology of extracting bone marrow mononuclear cells from the autologous patient and injecting into the lesion of...
Liver engrafting cells, assays, and uses thereof
Patent Number: 7,211,404Hepatic diseases are a major scourge on our society. Currently great progress has been made through the use of autologous bone marrow stem cells for treatment of these diseases. In the current patent, a cell that is capable of engrafting in the liver is disclosed. the cell is of hepatic origin and is positive for 5E12 and/or Ep-Cam and/or CD49f and/or E-Cadherin...
Gene transfer into primate embryonic stem cells using VSV-G pseudotyped simian immunodeficiency virus vectors
Patent Number: 7,323,337This patent covers methods of transfecting embryonic stem cells. Specifically, it claims the use of SIV genetically engineered so that the nucleic acid which is being transfected is packaged into an SIV virion. Specific proteins and strains of SIV are covered that are useful for transfection. Numerous...
Method of testing myelotoxicity with the use of flow cytometer
Patent Number: 7,300,763Development of chemotherapeutic drugs is dependent on proper animal preclinical toxicology systems. These systems are very important since chemotherapeutic drugs usually have a very small margin in which tumor toxicity is achieved but healthy tissue is not completely destroyed. One of the first body systems to go during chemotherapeutic dose escalation is the hematopoietic system. This...
Methods and compositions for diagnosing and monitoring transplant rejection
Patent Number: 7,235,358As science progresses to the point of inducing specific differentiation of cellular products from embryonic stem cells, the issue of allogeneic rejection will have to be dealt with. This specific patent provides various inflammatory markers that are useful for knowing when a rejection episode will occur. By identifying when a transplanted cellular product starts undergoing rejection, it...
Genes with ES cell-specific expression
Patent Number: 7,250,255Genes associated with pluripotency, or "stemness" are very important not only from a scientific research perspective, but also from the perspective of clinically developing stem cell therapeutics. Specifically, during clinical development of any biological, it is important to possess numerous quality control assays. The current patent covers a novel gene whose expression seems to be...
Use of osteopontin for the treatment and/or prevention of neurologic diseases
Patent Number: 7,297,099Osteopontin is a cytokine molecule that is involved in tumor metastasis and various immune functions.
In the current invention, osteopontin is used to treat chemotherapy-induced neurotoxicity. This is essentially a next step from the previous work of the same inventors who previously patented the use of osteopontin for... In the manufacture of various implantable medical devices it is important that the said device be able to endothelialize so that it integrates successfully with the host. When this doesn't happen various problems may arise such as restenosis, or inflammation at the site of device implantation.
The current patent teaches that coating of devices with osteoprotegerin can be used to cause... This patent teaches how to administer bone marrow in vivo, so that administration is performed not only of hematopoietic stem cells, but also stromal elements. This combination should be useful in patients whose stroma has been destroyed for one reason or another. The invention may also be useful for prevention of donor-derived leukemic relapse. This patent teaches ways of inactivating xenogeneic carbohydrate antigens and replacing them with non-immunogenic antigens so that various porcine and animal tissue may be transplanted into humans without the fear of hyperacute rejection.
Since the problem of allogeneic rejection is still an issue, the clinical translation of this technology will most likely be long-term. Specifically, if...
Methods and devices for promoting endothelial morphogenesis
Patent Number: 7,198,798
Composite bone marrow graft material with method and kit
Patent Number: 6723131
Animal tissue with carbohydrate antigens compatible for human transplantation
Patent Number: 7,126,039